검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cell function identification (Cell function identification) Fondazione Policlinico Universitar…·Bronchiolitis Obliterans Syndrome … 46 trials |
|---|---|
Overview Program | Cell function identification |
Overview Company | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Overview Modality | CGT |
Overview Target | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Indication | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target was knocked down using RNA interference, then the PrsA- or SS2-induced corresponding cells death were determined via LDH release and LIVE/DEAD staining, with its downstream pathway |
MoA Biomarker | biomarkers, namely the neutrophil-to-lymphocyte count ratio (NLCR) and platelet-to-lymphocyte count ratio (PL |
PK/PD Species | Mouse, Critically |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Critically |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.. The identification of small molecule modulators of immune checkpoint proteins remains a significant challenge in drug discovery due to the flat, featureless nature of protein-protein interaction interfaces and the characteristically low hit rates observed… |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cell function identification (Cell function identification) Fondazione Policlinico Universitar…·Bronchiolitis Obliterans Syndrome … 46 trials |
|---|---|
Overview Program | Cell function identification |
Overview Company | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Overview Modality | CGT |
Overview Target | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Indication | Bronchiolitis Obliterans Syndrome (BOS) |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | target was knocked down using RNA interference, then the PrsA- or SS2-induced corresponding cells death were determined via LDH release and LIVE/DEAD staining, with its downstream pathway |
MoA Biomarker | biomarkers, namely the neutrophil-to-lymphocyte count ratio (NLCR) and platelet-to-lymphocyte count ratio (PL |
PK/PD Species | Mouse, Critically |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Critically |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.. The identification of small molecule modulators of immune checkpoint proteins remains a significant challenge in drug discovery due to the flat, featureless nature of protein-protein interaction interfaces and the characteristically low hit rates observed… |
Clinical Data Tier / Score | A · 20 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교